The size of the Cell-Based Assay Market in Europe was worth USD 4.03 billion in 2019 and estimated to be growing at a CAGR of 10.84%, to reach USD 6.74 billion by 2024. Europe is the second-largest cell-based assay market.
Pharmaceutical and biotech companies are trying to improve efficiencies and reduce costs associated with drug discovery. Several vendors are turning to cell-based assays as a substitute to biochemical assays and in-vitro testing, as they can be used for various applications, such as recognition and validation of targets, selection for efficacy and safety, and monitoring of cell-based activity – all with a guarantee of highly accurate data.
Market growth is mainly driven by the interest in drug discovery technology, toxicity screening, and developments within the screening industry, and an increasing number of target molecules. Another factor contributing to the rapid growth of the cell-based assay market includes the trend to use automated systems and high throughput screening (HTS) processes.
Lack of skilled professionals is hindering the growth of the cell-based assay market.
This research report segmented and sub-segmented into the following categories:
Regionally, Spain and Italy are the fastest emerging markets in the European region for cell-based assay market.
Noteworthy companies leading the European Cell-Based Assay Market profiled in this report are Thermo Fisher Scientific Inc., Becton & Dickinson and Company, Merck & Co. Inc., Cell Signalling Technology Inc., PerkinElmer Inc., Danaher Corporation, General Electric Company, Cisbio Bioassays, DiscoveRx, Ametek Inc., Bio-Rad Laboratories, Roche Diagnostics, GE Healthcare and Promega Corporation.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type of Product
5.1.1 Introduction
5.1.2 Cell Lines
5.1.2.1 Primary Cell Lines
5.1.2.2 Stem Cell Lines
5.1.2.3 Immortalized Cell Lines
5.1.3 Assay Ready Kits
5.1.4 Cell Culture Kits
5.1.5 Reagents & Consumables
5.1.6 Ligands & Inhibitors
5.1.7 Y-o-Y Growth Analysis, By Type of Product
5.1.8 Market Attractiveness Analysis, By Type of Product
5.1.9 Market Share Analysis, By Type of Product
5.2 Technology
5.2.1 Introduction
5.2.2 Automated Handling
5.2.3 Flow Cytometry
5.2.4 Label-Free Detection
5.2.5 High Content Screening
5.2.6 High Throughput Screening
5.2.7 Y-o-Y Growth Analysis, By Technology
5.2.8 Market Attractiveness Analysis, By Technology
5.2.9 Market Share Analysis, By Technology
5.3 Application
5.3.1 Introduction
5.3.2 Drug Discovery
5.3.3 ADME Research
5.3.7 Y-o-Y Growth Analysis, By Application
5.3.8 Market Attractiveness Analysis, By Application
5.3.9 Market Share Analysis, By Application
5.4 End User
5.4.1 Introduction
5.4.2 Academia
5.4.3 Biotechnology
5.4.4 Pharmaceuticals
5.4.5 CRO
5.4.6 Y-o-Y Growth Analysis, By End User
5.4.7 Market Attractiveness Analysis, By End User
5.4.8 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Type of Product
6.1.3.3 By Technology
6.1.3.4 By Application
6.1.3.5 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Type of Product
6.1.4.3 By Technology
6.1.4.4 By Application
6.1.4.5 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Technology
6.1.5.3 By Type
6.1.5.4 By Application
6.1.5.5 By End User
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Thermo Fisher Scientific Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Becton
8.3 Dickinson and Company
8.4 Merck & Co. Inc.
8.5 Cell Signalling Technology Inc.
8.6 PerkinElmer Inc.,
8.7 Danaher Corporation
8.8 General Electric Company
8.9 Cisbio Bioassays
8.10 DiscoveRx
8.11 Ametek Inc.
8.12 -Rad Laboratories
8.13 Roche Diagnostics
8.14 GE Healthcare
8.15 Promega Corporation
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
